The CD300e molecule in mice is an immune-activating receptor

Masamichi Isobe, Kumi Izawa, Masahiro Sugiuichi, Tamami Sakanishi, Ayako Kaitani, Ayako Takamori, Akie Maehara, Toshihiro Matsukawa, Mariko Takahashi, Yoshinori Yamanishi, Toshihiko Oki, Shino Uchida, Koichiro Uchida, Tomoaki Ando, Keiko Maeda, Nobuhiro Nakano, Hideo Yagita, Toshiyuki Takai, Hideoki Ogawa, Ko Okumura, Toshio Kitamura, and Jiro Kitaura

From the 4Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, the 5Division of Cellular Therapy/Division of Stem Cell Signaling, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, the 6Laboratory of Cell Biology, Research Support Center, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, the 7Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-0808, the 8**Department of Immune Regulation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, the Departments of 9**Gastroenterology Immunology and 10Gastroenterology Immunology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, and the 11**Department of Experimental Immunology, Institute of Development, Aging, and Cancer, Tohoku University, 4-1 Seiryo, Sendai 980-8575, Japan

Edited by Peter Cresswell

CD300 molecules (CD300s) belong to paired activating and inhibitory receptor families, which mediate immune responses. Human CD300e (hCD300e) is expressed in monocytes and myeloid dendritic cells and transmits an immune-activating signal by interacting with DNA-activating protein (DAP12). However, the CD300e ortholog in mice (mCD300e) is poorly characterized. Here, we found that mCD300e is also an immune-activating receptor. We found that mCD300e engagement triggers cytokine production in mCD300e–transduced bone marrow–derived mast cells (BMMCs). Loss of DAP12 and another signaling protein, FcRγ, did not affect surface expression of transduced mCD300e, but abrogated mCD300e–mediated cytokine production in the BMMCs. Co-immunoprecipitation experiments revealed that mCD300e physically interacts with both FcRγ and DAP12, suggesting that mCD300e delivers an activating signal via these two proteins. Binding and reporter assays with the mCD300e extracellular domain identified sphingomyelin as a ligand of both mCD300e and hCD300e. Notably, the binding of sphingomyelin to mCD300e stimulated cytokine production in the transduced BMMCs in an FcRγ- and DAP12-dependent manner. Flow cytometric analysis with an mCD300e–specific Ab disclosed that mCD300e expression is highly restricted to CD115 Ly-6Clow/int peripheral blood monocytes, corresponding to CD14dim/CD16+ human nonclassical and intermediate monocytes. Loss of FcRγ or DAP12 lowered the surface expression of endogenous mCD300e in the CD115 Ly-6Clow/int monocytes. Stimulation with sphingomyelin failed to activate the CD115 Ly-6Clow/int mouse monocytes, but induced hCD300e–mediated cytokine production in the CD14dim/CD16+ human monocytes. Taken together, these observations indicate that mCD300e recognizes sphingomyelin and thereby regulates nonclassical and intermediate monocyte functions through FcRγ and DAP12.

A variety of paired activating and inhibitory receptor families, including immunoglobulin-like receptors and C-type lectin-like receptors, regulate immune responses (1–3). CD300 (also called leukocyte mono-immunoglobulin-like receptor (LMIR)), CMRF-35-like molecule (CLM), myeloid-associated immunoglobulin-like receptor, or immune receptor expressed by myeloid cell) belongs to paired immunoglobulin-like receptor families (4–13). CD300 members are mainly expressed in myeloid cells and contain a highly homologous single immunoglobulin-like domain in their extracellular regions; CD300a (LMIR1 or CLM-8) and CD300f (LMIR3 or CLM-1) are inhibitory receptors that harbor immunoreceptor tyrosine-based inhibitory motif in their cytoplasmic regions, whereas other CD300 members are thought to be activating receptors that are coupled with adaptor proteins (e.g. FcRγ and DNA-activating protein 12 (DAP12)) bearing immunoreceptor tyrosine-based activating motif (ITAM) (4–13). Multiple studies showed that lipids or lipid-binding proteins act as ligands for several members of the mouse and human CD300 family (14–20). For example, the recognition of ceramide by mouse CD300f or ceramide by mouse CD300g (15, 16) was shown to activate the CD300f/Ly-6Clow/int monocytes, indicating that CD300 molecules serve as immune-activating receptors in myeloid cells.

3 The abbreviations used are: LMIR, leukocyte mono-immunoglobulin-like receptor; mCD300e, mouse CD300e; hCD300e, human CD300e; CLM, CMRF-35-like molecule; ITAM, immunoreceptor tyrosine-based activating motif; BMCC, bone marrow–derived mast cell; BM, bone marrow; PB, peripheral blood; BMmDC, BM-derived myeloid dendritic cell; BMpDC, BM-derived plasmacytoid dendritic cell; BMHd, BM-derived macrophage; R-PE, r-phyceroerythrin; APC, allophycocyanin; IRES, internal ribosome entry sites; PMA, phorbol 12-myristate 13-acetate; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SLAM, signaling lymphocyte-activating molecule; CNS, central nervous system; Ab, antibody; DAP12, DNA-activating protein 12.
Mouse CD300e expression in nonclassical monocytes

Summary

CD300e, also called LMIR6 or monocytes (10, 13). However, the CD300e ortholog in mice leads to cytokine production in human peripheral blood (PB) linking of DAP12-coupled hCD300e with its specific antibody expressed in monocytes and myeloid dendritic cells. Cross-identified sphingomyelin as a candidate ligand for mouse assays (15, 27, 28) using the extracellular domain of CD300e. Moreover, both physical binding and functional reporter assays (15, 27, 28) using the extracellular domain of CD300e identified sphingomyelin as a candidate ligand for mouse and human CD300e.

Sphingomyelin is the most abundant sphingolipid in the cell and lipoprotein components. It is an essential element of plasma membrane that is crucial for cellular function (29, 30). In addition, it is abundant in the central nervous system (CNS); the levels of sphingomyelin in CNS are reported to be associated with the pathologies of CNS diseases, including ischemia/hypoxia, Alzheimer’s disease, and Parkinson’s disease (30).

Currently, three types of monocytes are classified in humans and mice. In humans, CD14⁺CD16⁺, CD14⁺CD16⁻, and CD14⁺CD16⁻ monocytes are classical, nonclassical (patrolling), and intermediate monocytes, respectively. These three types of monocyte populations correspond to CD115⁺Ly-6Clow/int PB monocytes. Moreover, both physical binding and functional reporter assays (15, 27, 28) using the extracellular domain of CD300e identified sphingomyelin as a candidate ligand for mouse and human CD300e.

Results

mCD300e is an N-glycosylated surface receptor

The full-length cDNA of mCD300e was isolated by PCR from a cDNA library of C57BL/6J mouse-derived bone marrow (BM) cells. The mCD300e protein is composed of an N-terminal signal peptide, extracellular region containing a single V-type immunoglobulin-like domain, transmembrane domain containing a positively-charged amino acid residue lysine, and short cytoplasmic tail without any signaling motif. The immunoglobulin-like domain of mCD300e shares 41% amino acid sequence identity with that of mouse CD300f, which is an inhibitory receptor (Fig. 1A). To analyze the function of mCD300e, FLAG-tagged mCD300e was transduced into Ba/F3, a pro-B cell line. Flow cytometric analysis showed that anti-FLAG antibody (Ab) specifically stained FLAG-tagged mCD300e on the surface of the transduced Ba/F3 cells, but not of the mock-transduced cells, demonstrating that mCD300e is a cell-surface receptor (Fig. 1B). Western blot analysis showed that FLAG-tagged mCD300e transduced into Ba/F3 cells was detected by anti-FLAG Ab as two discrete bands with differing mobilities (28–34 and 19 kDa) (Fig. 1C). Because an N-glycosylation site (asparagine at residue 84) is present within the immunoglobulin domain of mCD300e, we pretreated the same cell lysates with N-glycosidase F. The results showed that this pretreatment shifted the mobilities of the two forms of FLAG-tagged mCD300e (24–26 and 18 kDa) (Fig. 1C). Notably, FLAG-tagged mCD300e-N84Q, in which asparagine (N) at residue 84 was replaced with glutamine (Q), transduced into Ba/F3 cells was detected as two bands (24–26 and 18 kDa), nearly identical to those in the case of FLAG-tagged mCD300e after treatment with N-glycosidase F (Fig. 1C). In addition, treatment with N-glycosidase F no longer influenced the apparent molecular masses of FLAG-tagged mCD300e-N84Q (Fig. 1C). Because a positively charged amino acid residue lysine is present at residue 179 (Lys179) within the transmembrane domain of mCD300e, we asked whether mCD300e could be coupled with an ITAM-containing adaptor protein that harbors a negatively charged residue in its transmembrane domain. We further performed co-immunoprecipitation experiments using HEK 293T cells transiently expressing FLAG-tagged mCD300e together with either Myc-tagged FcRγ or DAP12. The results showed that both FcRγ and DAP12 were co-immunoprecipitated with mCD300e (Fig. 1D), indicating their roles as candidate adaptor proteins for mCD300e. Collectively, mCD300e is an N-glycosylated surface receptor that can be coupled with ITAM-containing adaptor proteins FcRγ and DAP12.

mCD300e can deliver an activating signal in BMMC transfectants in both FcRγ- and DAP12-dependent manner

Because mouse CD300 members are mainly expressed in myeloid cells, FLAG-tagged mCD300e was transduced into BMMCs for further investigation of mCD300e function. Flow cytometric analysis confirmed that BMMCs transduced with FLAG-tagged mCD300e or mock-exhibited equivalent levels of c-Kit and FceRI, both of which are mast cell-surface markers (7, 45) and that the former transfectants, but not latter, expressed FLAG-tagged mCD300e on the cell surfaces (Fig. 2A). Culture-
ing the two types of BMMC transfectants on plates coated with anti-FLAG Ab revealed robust production of IL-6 in the BMMCs transduced with FLAG-tagged mCD300e, but not in mock transfectants (Fig. 2B). In contrast, stimulation with phorbol 12-myristate 13-acetate (PMA) induced comparable levels of IL-6 production in the two types of transfectants (Fig. 2B). These results indicate that mCD300e can act as an activating receptor. Next, to identify ITAM-containing adaptor pro-

| BMMC Transfectants | Activating Receptor |
|--------------------|---------------------|
| CD300e/LMIR6/CLM-2 |                    |
| CD300b/LMIR5/CLM-7 |                    |
| LMR7/CLM-3         |                    |
| LMR4/CLM-5         |                    |
| CD300f/LMIR3/CLM-1 | Inhibitory Receptor |

---

**Figure 1.** mCD300e is an N-glycosylated surface receptor. A, the phylogenetic tree of mouse LMIR3 (CLM-1/CD300f), LMIR4 (CLM-5), LMIR5 (CLM-7/CD300b), LMIR6 (CLM-2/CD300e), and LMIR7 (CLM-3) is shown on the basis of homology with the immunoglobulin-like domain (upper panel). The percentage of amino acid sequence identity of the immunoglobulin-like domain is indicated. Alignment of amino acid sequences for mCD300e is shown (lower panel). The putative signal sequence is shown in lowercase. An immunoglobulin-like domain is boxed. The transmembrane domain is underlined. The potential N-linked glycosylation site is shaded. The positively charged amino acid residue lysine within the transmembrane domain is shown in bold. B, Ba/F3 cells were transduced with FLAG-tagged mCD300e or mock. The transfectants were stained with mouse anti-FLAG Ab or mouse IgG1 Ab followed by PE-conjugated anti-mouse IgG goat F(ab')2 Ab. C, lysates of Ba/F3 cells expressing FLAG-tagged mCD300e, mCD300e-N84Q, or mock were pretreated with or without N-glycosidase F before immunoprecipitation with mouse anti-FLAG Ab and subsequently immunoblotted with rabbit anti-FLAG Ab. D, 293T cells were transiently co-transfected with FLAG-tagged mCD300e construct or mock together with Myc-tagged FcRγ or DAP12 construct or mock. Immunoprecipitates of lysates of these transfectants with mouse anti-FLAG Ab were probed with anti-Myc Ab or rabbit anti-FLAG Ab. B–D, a representative of three independent experiments is shown. N-Gly, IB, or IP indicates N-glycosidase F, immunoblot, or immunoprecipitation, respectively.
proteins for mCD300e, BMMCs from Fcγ−/−, DAP12−/−, or Fcγ−/−DAP12−/− mice (25, 26) as well as WT mice were transduced with FLAG-tagged mCD300e. Flow cytometric analysis confirmed equivalent levels of c-Kit in these BMMC transfectants (Fig. 2C). Loss of Fcγ dampened the surface expression of FcεRI as expected (7), whereas loss of Fcγ and/or DAP12 failed to influence the surface expression levels of the transduced FLAG-tagged mCD300e (Fig. 2C). We then stimulated these BMMC transfectants with plate-coated anti-FLAG Ab or control Ab. The results showed that deficiency of Fcγ or DAP12 significantly lowered mCD300e-mediated IL-6 production (Fig. 2D). Remarkably, deficiency of both Fcγ and DAP12 abrogated mCD300e-mediated IL-6 production in BMMC transfectants (Fig. 2D). In contrast, stimulation with PMA induced comparable levels of IL-6 production in the transfectants tested (Fig. 2D). Collectively, both Fcγ and DAP12 were dispensable for maintaining surface expression of the transduced mCD300e; however, one or the other of the proteins were indispensable for mCD300e-mediated activation of BMMC transfectants.

**Generation of specific antibody against mCD300e**

To examine the mRNA expression profiles of mCD300e, we performed quantitative real-time PCR analysis using various mouse tissues. We found significantly higher expression levels of mCD300e in PB cells as compared with that in other tissues, although mCD300e expression was detected in the lung, liver, spleen, and BM (Fig. 3A). This suggests that mCD300e expression is restricted mainly to circulating PB cells and, to a lesser extent, possibly to tissues with abundant vascularity. To further examine mCD300e protein expression profiles in hematopoietic cells, we generated an Armenian hamster anti-mCD300e monoclonal Ab. To confirm the specificity of this Ab, Ba/F3 cells were transduced with FLAG-tagged mouse LMIR1/CLM-8 (CD300a), LMIR2/CLM-4, LMIR3/CLM-1 (CD300f), LMIR4/CLM-5, LMIR5/CLM-7 (CD300b), LMIR6/CLM-2...
We found that monoclonal anti-mCD300e Ab recognized the transduced mCD300e in Ba/F3 cells; however, it did not detect other LMIRs transduced into Ba/F3 cells (Fig. 3B). In addition, we found that plate-coated anti-mCD300e Ab remarkably induced IL-6 production in mCD300e-transduced BMMC transfectants, but not in mock transfectants (Fig. 3C). Thus, we succeeded in generating a monoclonal Ab specific for mCD300e.

Because high levels of mCD300e mRNA were found in PB cells, we stained PB cells with the monoclonal anti-mCD300e Ab. The results showed that mCD300e was not expressed in CD3+ T cells, CD19+ B cells, or Ly-6G+ neutrophils in PB (Fig. 4A). By contrast, mCD300e was selectively expressed in a small subset of cell populations in PB, which was CD11b+CD11c−F4/80−CD80highCD86−MHC-II+, suggesting that mCD300e is expressed in monocyte-lineage cells in PB (Fig. 4B). Because mouse PB monocytes are divided into three subpopulations (CD11b+CD11c+Ly-6Chigh, CD11b+CD11c+Ly-6Cint, and CD11b+CD11c−Ly-6Clow), we examined the surface expression of mCD300e in these populations, demonstrating that mCD300e is expressed highly in CD11b+Ly-6Clow nonclassical (patrolling) monocytes and moderately in CD11b+Ly-6Cint intermediate monocytes, but not in CD11b+Ly-6Chigh classical monocytes (Fig. 4, C and D) (31–33). In contrast, CD80highmCD300e+ cells were not detectable in the spleen,
thymus, or BM (Fig. 4E). In addition, we found no detectable levels of mCD300e in BMMCs, BM-derived myeloid dendritic cells (BMmDCs), BM-derived plasmacytoid dendritic cells (BMPDCs), or BM-derived macrophages (BMMφ) (Fig. 4F).

Flow cytometric analysis of CD115\(^+\)Ly-6C\(^{\text{low/int}}\) PB monocytes from WT, FcRγ\(^{-/-}\), DAP12\(^{-/-}\), or FcRγ\(^{-/-}\)DAP12\(^{-/-}\) mice showed that loss of either FcRγ or DAP12 lowered the surface expression levels of endogenous mCD300e, unlike the trans-
duced mCD300e in BMMCs (Fig. 4G). Thus, mCD300e expression was highly restricted to CD115$^+$ Ly-6C$^{low/int}$ monocytes in PB and possibly to a small subset of the related lineage cells in tissues.

**Sphingomyelin is a candidate ligand for mCD300e**

To identify the ligand that binds to mCD300e, we performed both binding and reporter assays using the extracellular domain of mCD300e. Because ceramide and sphingolipids have previously been identified as ligands for several CD300 members in mice and humans (15–20), we first asked whether ceramide and sphingolipids could bind to mCD300e–Fc, in which the extracellular domain of mCD300e was fused to the Fc portion of human IgG1. The results showed that mCD300e–Fc, but not control Fc, significantly bound to plate-coated sphingomyelin among the lipids tested (Fig. 5A). We then generated reporter cell lines mCD300e–2B4-GFP, where a chimeric receptor comprised of the extracellular domain of FLAG-tagged mCD300e, the transmembrane domain of mouse CD300f, and the intracellular domain of ITAM-bearing human CD3$^+$ was transduced into the parental reporter cell line 2B4-GFP (15, 27, 28). Because GFP expression is induced by the activation of nuclear factor of activated T-cells in 2B4-GFP cells, the binding of mCD300e ligands to this chimera receptor would be expected to induce GFP expression in mCD300e–2B4-GFP cells. Notably, plate-coated sphingomyelin as well as anti-FLAG Ab-induced GFP expression in mCD300e–2B4-GFP cells, but not in 2B4-GFP cells (Fig. 5B). In contrast, GFP expression was not induced by other plate-coated lipids tested (Fig. 5B). In addition, pretreatment with the soluble anti-mCD300e Ab, but not with control Ab, abolished sphingomyelin-mediated GFP expression in mCD300e–2B4-GFP cells (Fig. 5C). These results indicate that sphingomyelin is a candidate ligand for mCD300e.

**Sphingomyelin is a possible ligand for CD300e**

To test whether sphingomyelin acts as a ligand of mCD300e, FLAG-tagged mCD300e-transduced BMMCs were stimulated with plate-coated sphingomyelin or vehicle, and plate-coated sphingomyelin, but not vehicle, significantly induced IL-6 production in the BMMC transfectants (Fig. 6A). Pretreatment with the soluble anti-mCD300e Ab, but not control Ab, substantially reduced the cytokine production in mCD300e-transduced BMMCs stimulated by plate-coated sphingomyelin (Fig. 6A). Moreover, the deficiency of either FcR$^γ$ or DAP12 decreased IL-6 production induced by the sphingomyelin–mCD300e interaction in the BMMC transfectants, whereas the loss of both FcR$^γ$ and DAP12 dampened the IL-6 levels (Fig. 6B). However, CD115$^+$ Ly-6C$^{low/int}$ monocytes sorted from mouse PB failed to produce detectable levels of IL-6 in response...
Figure 6. A possible role of the sphingomyelin–CD300e interaction. A and B, IL-6 released into the culture supernatants were measured by ELISA. All data points correspond to the mean ± S.D. of four independent experiments. Statistically significant differences are shown. *, p < 0.05 or **, p < 0.01 (Student’s t test). A, BMMCs transduced with FLAG-tagged mCD300e were stimulated with plate-coated sphingomyelin or vehicle in the presence of 20 μg/ml of either soluble anti-mCD300e Ab or Armenia hamster IgG Ab as a control. B, FLAG-tagged mCD300e-transduced BMMCs from WT, FcRγ−/−, DAP12−/−, or FcRγ−/−DAP12−/− mice were stimulated with plate-coated sphingomyelin or vehicle. C, Ba/F3 cells were transduced with FLAG-tagged human CD300a, CD300b, CD300c, CD300e, CD300f, or mock. The transfectants were stained either with mouse anti-FLAG Ab or mouse IgG1 Ab followed by PE-conjugated anti-mouse IgG goat F(ab’)2 Ab (upper panel) or with anti-hCD300e Ab (233804), anti-hCD300e Ab (233812), or rat IgG2a Ab followed by PE-conjugated anti-rat IgG goat F(ab’)2 Ab (middle and lower panels). D, flow cytometry of GFP expression of hCD300e–2B4-GFP cells or 2B4-GFP cells that were incubated for 24 h on plates coated with indicated lipids or with anti-FLAG Ab or anti-hCD300e Ab (233804). E, flow cytometry of GFP expression of hCD300e–2B4-GFP cells that were incubated for 24 h on plates coated with sphingomyelin in the presence of 20 μg/ml of either soluble anti-hCD300e Ab (233812) or rat IgG2a Ab as a control. F, human PB cells were stained with APC-conjugated anti-CD14 Ab and FITC-conjugated anti-CD16 Ab and with anti-hCD300e Ab (233812) or rat IgG2a Ab followed by PE-conjugated anti-rat IgG goat F(ab’)2 Ab. Expression of hCD300e in CD14+CD16+, CD14+CD16−, or CD14−CD16−PB cells was shown. C–F, data are representative of three independent experiments. G, CD14dimCD16+ cells sorted from human PB were stimulated with plate-coated sphingomyelin or vehicle in the presence of 20 μg/ml of either soluble anti-hCD300e Ab (233812) or rat IgG2a Ab as a control. The levels of IL-6 released into the culture supernatants were measured by ELISA. All data points correspond to the mean ± S.D. of three independent experiments. Statistically significant differences are shown. *, p < 0.05 or **, p < 0.01 (Student’s t test).
Mouse CD300e expression in nonclassical monocytes

to plate-coated sphingomyelin (data not shown), presumably in part due to reduced viability of these monocytes in culture. Nonetheless, we provided evidence that sphingomyelin could act as a ligand for mCD300e at least in transduced BMMCs. Next, we confirmed that two types of anti-hCD300e Abs (233804 and 233812) specifically recognized hCD300e, but not other members of human CD300 tested, on the transduced Ba/F3 cells (Fig. 6C). To further delineate whether sphingomyelin acts as a ligand for hCD300e as well, we generated the new reporter cells hCD300e–2B4-GFP in a similar way as mCD300e–2B4-GFP and stimulated them with plate-coated sphingomyelin. The results showed that plate-coated sphingo- myelin or anti-hCD300e Ab (233804), but not other lipids tested, induced GFP expression in hCD300e–2B4-GFP cells like in mCD300e–2B4-GFP cells (Fig. 6D). In addition, pretreatment with the soluble anti-hCD300e Ab (233812), but not with control Ab, significantly inhibited sphingomyelin-induced GFP expression in hCD300e–2B4-GFP cells (Fig. 6E).

Flow cytometric analysis verified that hCD300e was expressed in three subsets of human PB monocytes comprising CD14+/CD16−, CD14+/CD16+, and CD14+/CD16+ monocytes (Fig. 6F) (46). Notably, plate-coated sphingomyelin induced TNF-α production in CD14+/CD16+ nonclassical (patrolling) monocytes sorted from human PB (Fig. 6G). Pre-treatment with the soluble anti-hCD300e Ab (233812) reduced, but not completely, the cytokine production in sphingomyelin-stimulated CD14+/CD16+ monocytes (Fig. 6G), suggesting that sphingomyelin can act as a ligand for hCD300e.

Discussion

In the present study, we characterized mCD300e as an immune-activating receptor. Generation of monoclonal anti-mCD300e Ab that specifically recognize mCD300e and not other CD300 members enabled us to uncover expression profiles of mCD300e in mouse hematopoietic cells. Interestingly, mCD300e was highly expressed in CD115+Ly-6Clow nonclassical (patrolling) monocytes and moderately in CD115+Ly-6Cint intermediate monocytes, but not in CD115+Ly-6Chigh classical monocytes, in mouse PB. One of the characteristics of CD115+Ly-6Clow/int monocytes expressing mCD300e was the high expression levels of CD80, but not CD86. Notably, it was difficult to detect mCD300e expression in cell populations distinct from CD115+Ly-6Clow/int monocytes. Accordingly, mCD300e expression might be tightly regulated by transcription factors specific for intermediate and nonclassical (patrolling) monocytes. One such possible candidate is the transcription factor NUR77, also called NR4A1, that is essential for the development of Ly-6Clow monocytes (39, 47). The higher mRNA expression levels of mCD300e in the lung or spleen compared with those in BM led us to speculate that CD115+Ly-6Clow/int monocytes might preferentially reside in the vasculature of lung or spleen. Alternatively, CD115+Ly-6Clow circulating monocytes might differentiate into specialized monocyte/dendritic cell/macrophage lineage cells with mCD300e expression in the spleen or lung (31–33, 48, 49). Notably, CD300e expression profiles in hematopoietic cells differ between humans and mice; hCD300e is expressed in three subsets of monocytes and myeloid dendritic cells, whereas mCD300e expression is restricted to nonclassical (patrolling) and intermediate monocytes in PB and possibly to a small subset of the related lineage cells in tissues. In addition, this selective expression of mCD300e suggested a specialized role of mCD300e in patrolling monocytes.

Analysis of mCD300e-transduced BMMCs definitely demonstrated that similar to hCD300e, mCD300e can transmit an immune-activating signal (12, 13). However, unlike hCD300e that couples with DAP12 (12), mCD300e required both FcRγ and DAP12 as its adaptor proteins to fully transmit an activating signal. Similar to LMIr2 (CLM-4) (50), the relative contribution of FcRγ versus DAP12 to the activating signals through mCD300e might be affected by the cellular environments. It is important to note that the loss of these adaptor proteins did not influence the surface expression levels of transduced mCD300e, but reduced those of endogenous mCD300e in the intermediate and nonclassical monocytes. Collectively, these results suggest that FcRγ and DAP12 are required not only for delivering the maximum activating signal but also for maintaining the maximum surface expression of mCD300e in intermediate and nonclassical monocytes.

Importantly, we identified sphingomyelin as a candidate ligand for both mouse and human CD300e by binding and reporter assays. In fact, plate-coated sphingomyelin stimulated significant cytokine production in transduced BMMCs via mCD300e; however, the same treatment did not do so in the case of CD115+Ly-6Clow/int monocytes from mouse PB. Different expression levels of mCD300e between transduced BMMCs and CD115+Ly-6Clow/int monocytes might account for such different responses. Alternatively, the low viability of CD115+Ly-6Clow/int monocytes in the culture possibly masked their activation in response to sphingomyelin. To gain evidence that sphingomyelin acts as a ligand for mCD300e in CD115+Ly-6Clow/int monocytes, further examination will be required. On the other hand, it is possible that sphingomyelin-like lipids, either endogenous or exogenous, with stronger affinity to mCD300e might serve as its physiological ligands, which also remain to be further investigated. Sphingomyelin being abundant in lipoproteins or the CNS, the binding of sphingomyelin-containing lipoprotein or sphingomyelin released from injured CNS to mCD300e might regulate vascular inflammation in arteriosclerosis or the pathogenesis of the CNS diseases, respectively (30, 39–43). Moreover, it is interesting to speculate that mCD300e contributes to the engulfment of sphingomyelin-containing debris from damaged tissues by the patrolling monocytes (31–34). Ultimately, analysis of CD300e-deficient mice will be needed to completely understand the physiological significance of the CD300e-sphingomyelin interaction.

In conclusion, mouse CD300e is an activating receptor coupled with FcRγ and DAP12, which is selectively expressed in nonclassical and intermediate monocytes in circulating monocytes, implicating CD300e in the disease pathogenesis involving non-classical monocyte activation.
**Mouse CD300e expression in nonclassical monocytes**

**Materials and methods**

**Cells and mice**

Murine cell lines Ba/F3 and 2B4-GFP (a kind gift from Takashi Saito, RIKEN Research Center for Allergy and Immunology, Yokohama, Japan) and human cell line HEK 293T were previously used (7, 15, 27, 28). BM, spleen, or thymus cells were isolated from C57BL/6 mice or FcRγ−/−, DAP12−/−, or FcRγ−/−DAP12−/− mice (25, 26). BMMCs were generated and cultured as described (15, 45). All the procedures were approved by the Institutional Review Committee of University of Tokyo and Juntendo University. CD14dimCD16+ monocytes were sorted from human PB. All human subjects provided written informed consent in accordance with the Helsinki Declaration of the World Medicine Association. The study was approved by the Ethics Committee of and University of Tokyo and Juntendo University.

**Antibodies and other reagents**

Armenian hamster anti-mouse CD300e monoclonal IgG Ab was generated by immunizing Armenian hamster with mouse CD300e-Fc, as previously described (51, 52). The following antibodies were used in this study: rat anti-human CD300e monoclonal IgG2a Abs (233804 and 233812) (R&D Systems); anti-FLAG Ab (M2) and mouse IgG1 Ab (MOPC21) (Sigma); anti-Myc Ab (9E10) (Roche Diagnostics); Armenian hamster IgG Ab, FITC-conjugated anti-mouse FcεRlα Ab, and R-phycocerythrin (PE)-conjugated anti-mouse c-Kit Ab, CD11b, and B220 Abs or streptavidin (eBioscience); PE-conjugated anti-rat IgG goat F(ab')2 Ab (Jackson ImmunoResearch); FITC-conjugated anti-human CD16 Ab (Miltenyi Biotech); rat IgG2a and FITC-conjugated anti-mouse CD3, CD19, Ly-6G, CD11b, CD11c, F4/80, Ly-6C, CD80, CD86, and MHC class II Abs (BioLegend); allophycocyanin (APC)-conjugated anti-human CD14 Ab (eBioscience); PE-conjugated anti-mouse IgG goat F(ab')2 Ab (Beckman Coulter). Anti-mCD300e Ab and Armenia hamster IgG Ab were biotinylated by sulfo-NHS-LC-biotin (Pierce, Thermo Fisher Scientific) according to the manufacturer’s instructions. Other reagents used in this study include cytokines (R&D Systems); peptide-N-glycosidase F (New England Biolabs); sphingosine, sphingomyelin, and cholesterol (Avanti Polar Lipids, Inc.); 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphoserine, and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (Echelon Biosciences Inc.). 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (Echelon Biosciences Inc.); 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-di-sn-glycero-3-phosphoethanolamine (Echelon Biosciences Inc.). All other reagents were from Sigma unless stated otherwise.

**Gene expression analysis**

Relative expression levels of mouse CD300e and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) among samples were measured by real-time RT-PCR as described (9). The following primers were used: 5'-GTCCATCAGAGACC-ATGCTTCG-3' and 5'-ACGTGACCAAGATCCACAG-3' for mCD300e and 5'-GAGGTTGAAGGTCGGAGTCA-3' and 5'-GACAAGCTTCCCGTTTTCAG-3' for GAPDH. Relative gene expression levels were calculated using standard curves generated by serial dilutions of cDNA and normalized to GAPDH expression levels. Product quality was checked by melting curve analysis via LightCycler software (Roche Diagnostics).

**Plasmid constructs**

cDNAs of mouse CD300e (GenBank™ accession number NM_172050.3) were isolated by PCR from a cDNA library of mouse BM cells. The cDNA fragment of mouse CD300e, lacking the signal sequence, was tagged with a FLAG epitope at the N terminus. The resultant FLAG-tagged mouse CD300e was subcloned into pMEs-internal ribosome entry sites (ires)–puromycinr (pMXs–ip) (54) to generate pMXs–FLAG–mCD300e–IP. pMXs–FLAG–mouse LMIR1, LMIR2, LMIR3, LMIR4, LMIR5, or LMIR7–IP was used previously (7–9). pMXs–FLAG–human CD300a, CD300b, CD300c, CD300e, or CD300f–IP was previously used (19). To generate the chimeric receptor mCD300e–CD3ζ, SLAM signal sequence–FLAG–mCD300e, excluding transmembrane and intracellular domains, was fused to the transmembrane domain of LMIR3 followed by the intracellular domain of human CD3ζ (Naoki Matsumoto, The University of Tokyo, Tokyo, Japan). To generate the chimeric receptor hCD300e–CD3ζ, SLAM signal sequence–FLAG–hCD300e, excluding transmembrane and intracellular domains, was fused to the transmembrane domain of human CD3ζ followed by the intracellular domain of human CD3ζ (Naoki Matsumoto, The University of Tokyo, Tokyo, Japan). mCD300e–CD3ζ or hCD300e–CD3ζ was subcloned into pMXs–IP to generate pMXs–FLAG–mCD300e–CD3ζ or FLAG–hCD300e–CD3ζ–IP (15, 19, 21). To generate the mCD300e–N84Q mutant, two-step PCR mutagenesis was performed using pMXs–FLAG–mCD300e–IP as a template. pMXs–Myc–mouse DAP12 or FcRg–ires–Blasticidinr (IB) was used as described previously (19). All constructs were verified by DNA sequencing.

**Flow cytometry**

Cells were stained as described (7–9, 15). Flow cytometric analysis was performed with FACSCalibur (BD Biosciences) equipped with CellQuest software and FlowJo software (Tree Star).

**Transfection and infection**

Retroviral transfection and infection were performed as described (7–9, 54, 55). Retroviruses were generated by transient transfection of PLAT-E packaging cells (55). Selection with 1 μg/ml of puromycin was started 48 h after infection.

**Biochemistry**

Western blotting was performed as described (7–9). Equal amounts of cell lysates of Ba/F3 transfectants or HEK 293T cells were immunoprecipitated with mouse anti-FLAG Ab or anti-Myc Ab, and immunoblotted with rabbit anti-FLAG Ab or anti-Myc Ab.
**Binding assay using solid-phase ELISA**

Solid-phase ELISA was performed to carry out the binding assays (14, 15). The Fc fusion proteins mCD300e–Fc and Fc were purified. The indicated lipids in methanol (50 μg/ml) or methanol as a control was added to ELISA plates and air-dried. After washing, the plates were incubated with 10 μg/ml of mCD300e–Fc or Fc in the presence of 0.5 mM CaCl₂ for 120 min before incubating with peroxidase-conjugated anti-human Ig (Sigma). Absorbance at 450 nm was measured.

**Measurement of cytokines**

To stimulate cells with plate-coated Ab, plates were coated overnight with 20 μg/ml of Ab before stimulation (15). To stimulate cells with plate-coated sphingomyelin, sphingomyelin in methanol (10 μg/ml) or methanol as control was added to plates and air-dried before stimulation (15). CD14dimCD16− monocytes sorted from human PB were stimulated with plate-coated sphingomyelin or vehicle for 24 h in the presence or absence of 10 μg/ml of a soluble anti-hCD300e Ab (233812) or rat IgG2a as control. BMMCs transduced with FLAG-tagged mCD300e–Fc or Fc in the presence of 0.5 mM CaCl₂ for 120 min before incubating with peroxidase-conjugated anti-human Ig (Sigma). Absorbance at 450 nm was measured.

**Concentrations of human TNF**

Measurement of cytokines

To stimulate cells with plate-coated Ab, plates were coated overnight with 20 μg/ml of Ab before stimulation (15). To stimulate cells with plate-coated sphingomyelin, sphingomyelin in methanol (10 μg/ml) or methanol as control was added to plates and air-dried before stimulation (15). CD14dimCD16− monocytes sorted from human PB were stimulated with plate-coated sphingomyelin or vehicle for 24 h in the presence or absence of 10 μg/ml of a soluble anti-hCD300e Ab (233812) or rat IgG2a as control. BMMCs transduced with FLAG-tagged mCD300e–Fc or Fc in the presence of 0.5 mM CaCl₂ for 120 min before incubating with peroxidase-conjugated anti-human Ig (Sigma). Absorbance at 450 nm was measured.

**Statistical analysis**

Data are shown as mean ± S.D., and statistical significance was determined by Student’s t test with *p < 0.05 or **p < 0.01 considered to indicate statistical significance.

**Author contributions**—M. I., K. I., T. T., H. O., K. O., and J. K. formal analysis; M. I., K. M., S., T., A. K. A., T., A. M., T. M., T. Y., Y. T., O., S. U., K. U., T. A., M. K., N. N., H. Y., T. T., and J. K. investigation; M. I. and J. K. methodology; M. I. writing-original draft; H. O., K. O., T. K., and J. K. supervision; T. K. and J. K. conceptualization; T. K. and J. K. project administration; J. K. funding acquisition; J. K. validation; J. K. writing-review and editing.

Acknowledgments—We thank Dr. Hisashi Arase and Dr. Naoki Matsumoto for providing cell lines. We also thank Dr. Takashi Saito for providing plasmids. We also thank Dr. Takashi Saito for providing plasmids. We also thank Dr. Takashi Saito for providing plasmids. We also thank Dr. Takashi Saito for providing plasmids.

**References**

1. Colonna, M. (2003) TREMs in the immune system and beyond. Nat. Rev. Immunol. 3, 445–453 CrossRef Medline
2. Ravetch, J. V., and Lanier, L. L. (2000) Immune inhibitory receptors. Science 290, 84–89 CrossRef Medline
3. Hardison, S. E., and Brown, G. D. (2012) C-type lectin receptors orchestrate antifungal immunity. Nat. Immunol. 13, 817–822 Medline
4. Chung, D. H., Humphrey, M. B., Nakamura, M. C., Ginzinger, D. G., Seaman, W. E., and Daws, M. R. (2003) CMRF-35-like molecule-1, a novel immune receptor restricted to the monocytic lineage. J. Immunol. 173, 6703–6711 CrossRef Medline
5. Yamashita, Y., Kitaura, J., Yamanishi, Y., Matsuoka, T., Oki, T., Kajikawa, M., Takai, T., Kitamura, T., and Kitaura, J. (2010) Characterization of leukocyte mono-immunoglobulin-like receptor (LMIR7)? (CLM-3) as an activating receptor: its similarities to and differences from LMIR4/CLM-5. J. Biol. Chem. 285, 35274–35283 CrossRef Medline
6. Nakahashi-Oda, C., Tahara-Hanaoka, S., Shoji, M., Okoshi, A., Sayós, J., and López-Botet, M. (2004) IREM-1 is a novel inhibitory receptor expressed by myeloid cells. Eur. J. Immunol. 34, 3690–3701 CrossRef Medline
7. Takahashi, M., Izawa, K., Kashiwakura, J., Yamanishi, Y., Enomoto, Y., Lu, Y., Shibata, F., Yamazaki, S., Nakajima, H., Maeda-Yamamoto, M., Maehara, A., Oki, T., Takamatsu, R., Kajikawa, M., Takai, T., Kitamura, T., and Kitaura, J. (2012) The receptor LMIR3 closely resembles mouse CD300a in ligand binding to extracellular ceramide. Immunity 37, 827–839 CrossRef Medline
8. Nakahashi-Oda, C., Tahara-Hanaoka, S., Shoji, M., Okoshi, A., Sayós, J., and López-Botet, M. (2004) Molecular characterization of a novel immune receptor restricted to the monocytic lineage. J. Immunol. 173, 6703–6711 CrossRef Medline
9. Izawa, K., Yamanishi, Y., Izawa, K., Kaitani, A., Takahashi, M., Maehara, A., Oki, T., Takamatsu, R., Kajikawa, M., Takai, T., Kitamura, T., and Kitaura, J. (2012) The receptor LMIR3 negatively regulates mast cell activation and allergic responses by binding to extracellular ceramide. Immunity 37, 827–839 CrossRef Medline

**Mouse CD300e expression in nonclassical monocytes**

Mouse CD300e expression in nonclassical monocytes

1. Colonna, M. (2003) TREMs in the immune system and beyond. Nat. Rev. Immunol. 3, 445–453 CrossRef Medline
2. Ravetch, J. V., and Lanier, L. L. (2000) Immune inhibitory receptors. Science 290, 84–89 CrossRef Medline
3. Hardison, S. E., and Brown, G. D. (2012) C-type lectin receptors orchestrate antifungal immunity. Nat. Immunol. 13, 817–822 Medline
4. Chung, D. H., Humphrey, M. B., Nakamura, M. C., Ginzinger, D. G., Seaman, W. E., and Daws, M. R. (2003) CMRF-35-like molecule-1, a novel immune receptor restricted to the monocytic lineage. J. Immunol. 173, 6703–6711 CrossRef Medline
5. Yamashita, Y., Kitaura, J., Yamanishi, Y., Matsuoka, T., Oki, T., Kajikawa, M., Takai, T., Kitamura, T., and Kitaura, J. (2010) Characterization of leukocyte mono-immunoglobulin-like receptor (LMIR7)? (CLM-3) as an activating receptor: its similarities to and differences from LMIR4/CLM-5. J. Biol. Chem. 285, 35274–35283 CrossRef Medline
6. Nakahashi-Oda, C., Tahara-Hanaoka, S., Shoji, M., Okoshi, A., Nakano-Yokomizo, T., Okhochi, N., Yasui, T., Kikutani, H., Honda, S., Shibuya, K., Nagata, S., and Shibuya, A. (2012) Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor. J. Exp. Med. 209, 1493–1503 CrossRef Medline
7. Tian, L., Choi, S. C., Murakami, Y., Allen, I., Morse, H. C., 3rd, Qi, C. F., Krzewski, K., and Colligan, J. E. (2014) p58授予 recruitment by the CD300f phosphatidylinerse receptor mediates apoptotic cell clearance required for autoimmunity suppression. Nat. Commun. 5, 3146 Medline
8. Cannon, J. F., O’Driscoll, M., and Litman, G. W. (2012) Specific lipid recognition is a general feature of CD300 and TREM molecules. Immuno- genetics 64, 39–47 Medline
9. Takahashi, M., Izawa, K., Kashiwakura, J., Yamanishi, Y., Enomoto, Y., Kaitani, A., Maehara, A., Isobe, M., Ito, S., Matsukawa, T., Nakahara, F., Oki, T., Kajikawa, M., Ra, C., Okayama, Y., Kitamura, T., and Kitaura, J. (2013) Human CD300C delivers an Fc receptor-γ-dependent activating signal in mast cells and monocytes and differs from CD300A in ligand recognition. J. Biol. Chem. 288, 7662–7675 CrossRef Medline
Mouse CD300e expression in nonclassical monocytes

20. Murakami, Y., Tian, L., Voss, O. H., Margulies, D. H., Krzewsii, K., and Coligan, J. E. (2014) CD300b regulates the phagocytosis of apoptotic cells via phosphatidylserine recognition. Cell Death Differ. 21, 1746–1757

21. Izawa, K., Isobe, M., Matsukawa, T., Ito, S., Maehara, A., Takahashi, M., Yamanishi, Y., Kaitani, A., Oki, T., Okumura, K., Kitamura, T., and Kitaura, J. (2014) Sphingomyelin and ceramide are physiological ligands for human LMR3/CD300f, inhibiting FcεRI-mediated mast cell activation. J. Allergy Clin. Immunol. 133, 270–273

22. Matsukawa, T., Izawa, K., Isobe, M., Takahashi, M., Maehara, A., Yamanishi, Y., Kaitani, A., Okumura, K., Teshima, T., Kitamura, T., and Kitaura, J. (2016) Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation. Gut 65, 777–787

23. Shiba, E., Izawa, K., Kaitani, A., Isobe, M., Maehara, A., Uchida, K., Maeda, K., Nakanou, N., Ogawa, H., Okumura, K., Kitamura, T., Shimizu, T., and Kitaura, J. (2017) Ceramide–CD300f binding inhibits lipopolysaccharide-induced skin inflammation. J. Biol. Chem. 292, 2924–2932

24. Izawa, K., Maehara, A., Isobe, M., Yasuda, Y., Uraii, M., Hoshino, Y., Ueno, K., Matsukawa, T., Takahashi, M., Kaitani, A., Shiba, E., Takamori, A., Uchida, S., Uchida, K., Maeda, K., et al. (2017) Disrupting ceramide-CD300f interaction prevents septic peritonitis by stimulating neutrophil recruitment. Sci. Rep. 7, 4298

25. Takai, T., Li, M., Sylvestre, D., Clynes, R., and Ravetch, J. V. (1994) FcRγ chain deletion results in pleiotropic effector cell defects. Cell 76, 519–529

26. Kaifu, T., Nakahara, J., Inui, M., Mishima, K., Moriyama, T., Kaji, M., Sugahara, A., Koito, H., Ujike-Asai, A., Nakamura, A., Kanazawa, K., Tan-Even, K., Iwaski, K., Yokoyama, W. M., Kudo, A., Fujikawa, M., Suedo, H., and Takai, T. (2003) Osteopetrosis and thalamic hypomyelination with synaptic degeneration in DAP12-deficient mice. J. Clin. Invest. 111, 323–332

27. Ohtsuka, M., Arase, H., Takeuchi, A., Yamasaki, S., Shiina, R., Suenaga, T., Ichinose, H., Shaked, I., Chodaczek, G., Biswas, S. K., and Hedrick, C. C. (2014) CADASIL: a rod-shaped monocyte sensor that regulates inflammatory signaling. Allergy Clin. Immunol. 137, 32693 CrossRef Medline

28. Yamasaki, S., Ishikawa, E., Sakuma, M., Hara, H., Ogata, K., and Kitamura, T. (2008) Membrane Attack Complex CD14–CD16, monocyte, and CD14–CD16, monocyte subpopulation. J. Clin. Invest. 117, 185–194

29. Arterioscler. Thromb. Vasc. Biol. 35, 1306–1316

30. Jakubzick, C. V., Randolph, G. J., and Henson, P. M. (2017) Monocyte differentiation and antigen-presenting functions. Nat. Rev. Immunol. 17, 349–362

31. Ginhoux, F., and Jung, S. (2014) Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 14, 392–404

32. Thomas, G., Tacke, F., Hedrick, C. C., and Hanna, R. (2015) Monocytic cells express membrane CD300e and CD14 as well as CD16. J. Immunol. 185, 985–990

33. Cros, J., Cagnard, N., Woollard, K., Patel, N., Zhang, S. Y., Senechal, B., Puel, A., Biswas, S. K., Moshous, D., Picard, C., Jais, J. P., D’Cruz, D., Casanova, J. L., Trouillet, C., and Geissmann, F. (2010) Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33, 375–386

34. hologram, D. K., 3rd., Berdnikovs, S, Filer, A., Clark, A. R., Buckley, C. D., Mutlu, G. M., Budinger, G. R., and Perlman, H. (2014) Naive and CD14 dim/CD16 + monocyte subsets do not differ in their ability to activate human macrophages. J. Biol. Chem. 289, 3037–3047

35. Thomas, G., Tacke, F., Ginhoux, F., Wagers, A. J., van Rooijen, N., Mack, M., Merad, M., and Randolph, G. J. (2008) Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117, 985–990

36. Nahrendorf, M., Swirski, F. K., Aikawa, E., Stangenberg, L., Wurdinger, T., Figueiredo, J. L., Libby, P., Weissleder, R., and Pittet, M. J. (2007) The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 204, 1007–1017

37. Slotte, J. P. (2013) Biological functions of abingomyelins. Prog. Lipid Res. 52, 424–437

38. Biemias, K., Fiedorowicz, A., Sadowska, A., Prokopiu, S., and Car, H. (2016) Regulation of sphingomyelin metabolism. Pharmacol. Rep. 68, 570–581

39. Shi, C., and Pamer, E. G. (2011) Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 11, 762–774

40. Jakubzick, C. V., Randolph, G. J., and Henson, P. M. (2017) Monocyte differentiation and antigen-presenting functions. Nat. Rev. Immunol. 17, 349–362

41. Landsman, L., Varol, C., and Jung, S. (2007) Distinct differentiation potential of bone marrow monocyte subsets in the lung. J. Immunol. 178, 2000–2007

42. Jakubzick, C., Tacke, F., Ginhoux, F., Wagers, A. J., van Rooijen, N., Mack, M., Merad, M., and Randolph, G. J. (2008) Blood monocyte subsets differentially give rise to CD103 + and CD103 – pulmonary dendritic cell populations. J. Immunol. 180, 3019–3027

43. Nakahashi, C., Tahara-Hankaoka, S., Totsuka, N., Okoshy, Y., Takai, T., Ohkohchi, N., Honda, S., Shibuia, K., and Shibuia, A. (2007) Dual assemblies of an activating immune receptor, MAIR-II, with ITAM-bearing adapters DAP12 and FcεRI chain on peritoneal macrophages. J. Immunol. 178, 765–770

44. Mori, T., Yasaki, S., Koyanagi, A., Koyama, N., Ogata, H., Chiba, S., Hirose, S., Okumura, K., and Yagita, H. (2008) Delta–1 is essential for the maintenance of marginal zone B cells in normal mice but not in autoimmune mice. Int. Immunol. 20, 763–773
52. Sakanishi, T., and Yagita, H. (2010) Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice. Biochem. Biophys. Res. Commun. 393, 829–835 CrossRef Medline

53. Shiratori, I., Ogasawara, K., Saito, T., Lanier, L. L., and Arase, H. (2004) Activation of natural killer cells and dendritic cells upon recognition of a novel CD99-like ligand by paired immunoglobulin-like type 2 receptor. J. Exp. Med. 199, 525–533 CrossRef Medline

54. Kitamura, T., Koshino, Y., Shibata, F., Oki, T., Nakajima, H., Nosaka, T., and Kumagai, H. (2003) Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp. Hematol. 31, 1007–1014 CrossRef Medline

55. Morita, S., Kojima, T., and Kitamura, T. (2000) Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7, 1063–1066 Medline